Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial

CIRCULATION

LIPPINCOTT WILLIAMS & WILKINS

1. Boehringer Ingelheim
2. Eli Lilly and Company Diabetes Alliance